Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Am J Emerg Med. 2021 Jun 29;49:343–351. doi: 10.1016/j.ajem.2021.06.049

Table 2.

Baseline characteristics

Received capsaicin (n = 149) Did not receive capsaicin (n = 52) p
Sex – Male (%) 68 (45.6) 24 (46.1) 0.34
Age – median, years (range) 31 (16–66) 27 (16–57) 0.19
Symptoms present – No. (%)
Nausea 118 (79.2) 43 (82.7) 0.59
Vomiting 135 (90.6) 48 (92.3) 0.71
Abdominal pain 108 (72.5) 39 (75) 0.72
Relief with hot showers 48 (32.2) 19 (36.5) 0.57
Duration of symptoms – No. (%) 0.69
< 1 week 93 (62.4) 29 (55.8)
≥1 week to < 1 month 27 (18.1) 11 (21.2)
≥1 month 26 (17.4) 11 (21.2)
Unknown/not specified 3 (2) 1 (1.9)

Cannabis length of Use – No. (%) 0.24

< 1 year 4 (2.7) 4 (7.7)
≥1 year 39 (26.2) 11 (21.2)
Unknown 106 (71.1) 37 (71.2)
Frequency of cannabis use – No. (%) 0.91
Less than once daily 39 (26.2) 15 (28.8)
At least once daily 85 (57) 28 (53.8)
Unknown 25 (16.8) 9 (17.3)
Type of cannabis use – No. (%)
Smoked 98 (65.8) 37 (71.2) 0.48
Other (not smoked) 7 (4.7) 3 (5.8) 0.60
Unknown 58 (38.9) 17 (32.7) 0.43
Pediatric emergency department patient – No. (%) 17 (11.4) 8 (15.4) 0.46
Time to administration of capsaicin or first agent – median, hours 3 1 <0.001